Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to ...

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

Saudi Arabia

◆ Source

Read at saudigazette.com.sa →

◆ Verified

Fusion42 · 23 August 2026 · Fusion42 review

The Saudi Food and Drug Authority (SFDA) is the first regulatory body worldwide to approve the registration of ZENBEXUS (iberdomide) for treating adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and dexamethasone.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now have a gateway to lead early access to ZENBEXUS in Saudi Arabia's oncology market, potentially setting a precedent for regional drug approvals.

◆ Coverage

1 source · 12 Aug 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalcancer-treatmentmultiple-myelomaregulatory-firstsaudi-arabia